Market Indices
Sector Heatmap
ATTR — Arin Tactical Tail Risk ETF
Cboe BZXArin Tactical Tail Risk ETF
- O
- 95.90
- H
- 95.90
- L
- 95.90
- V
- 230.18
ATTR — Latest News & Headlines
12 StoriesStabilizers, Silencers, and Depleters: Exploring New Frontiers Treating ATTR-CM - Pharmacy Times
Stabilizers, Silencers, and Depleters: Exploring New Frontiers Treating ATTR-CM Pharmacy Times
A former football player’s symptoms were attributed to football or aging. His heart diagnosis came late. - Stock Titan
A former football player’s symptoms were attributed to football or aging. His heart diagnosis came late. Stock Titan
BridgeBio Pharma Announces Real-World Study Showing Acoramidis Reduced Clinical Worsening Versus Tafamidis in ATTR-CM - Quiver Quantitative
BridgeBio Pharma Announces Real-World Study Showing Acoramidis Reduced Clinical Worsening Versus Tafamidis in ATTR-CM Quiver Quantitative
Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY) - Seeking Alpha
Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY) Seeking Alpha
Will RNAi Market Growth Change Alnylam Stock's Narrative? - Simply Wall Street
Will RNAi Market Growth Change Alnylam Stock's Narrative? Simply Wall Street
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM - Pharmacy Times
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM Pharmacy Times
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - tradingview.com
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation tradingview.com
Down 35% This Year, Alnylam Still Has Wall Street Calling 44% Upside - NAI500
Down 35% This Year, Alnylam Still Has Wall Street Calling 44% Upside NAI500
BridgeBio Pharma (BBIO) Following Acoramidis Study Faces A Wide Fair Value Debate - Simply Wall Street
BridgeBio Pharma (BBIO) Following Acoramidis Study Faces A Wide Fair Value Debate Simply Wall Street
BridgeBio Pharma stock gains attention as fresh inducement grants highlight growth plans - AD HOC NEWS
BridgeBio Pharma stock gains attention as fresh inducement grants highlight growth plans AD HOC NEWS
Real World Heart Study Altering The Investment Case For BridgeBio Pharma Stock? - Simply Wall Street
Real World Heart Study Altering The Investment Case For BridgeBio Pharma Stock? Simply Wall Street
BridgeBio Pharma (BBIO) Reports 34% Lower Risk Of Early Clinical Worsening - Simply Wall Street
BridgeBio Pharma (BBIO) Reports 34% Lower Risk Of Early Clinical Worsening Simply Wall Street